Deferred Treatment in Clinically Localised Prostatic Carcinoma

Abstract

A series of 122 patients with a cytological diagnosis of well or moderately differentiated and clinically localised (T1‐2) prostatic carcinoma were followed up without any initial anti‐tumour therapy. The median observation time was 91 months. During follow‐up the local tumour progressed to stage T3 in 67 patients (55%) and distant metastases developed in 17 (14%); 47 patients died (38%), 9 of them (7%) from prostatic carcinoma. The risk of dying from prostatic carcinoma was 1% after 5 years and 16% after 10 years for patients not dying from other causes.